A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Launched by BRISTOL-MYERS SQUIBB · Dec 12, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at why and how patients with Relapsing-Remitting Multiple Sclerosis (RRMS) switch their treatment to a medication called ozanimod. The study aims to gather information about the experiences of patients who have made this change. Researchers want to understand factors like the reasons for switching and how the disease and previous treatments have influenced this decision.

To participate in the trial, you need to have a confirmed diagnosis of RRMS and have switched from a previous treatment to ozanimod within the last 4 to 12 weeks. Additionally, you'll need to have had an MRI done in the past three months. If you decide to join, you can expect to share your experiences and follow-up with the research team during the study. This trial is currently recruiting participants of all genders, aged between 18 and 65. It's a chance to contribute valuable information that could help improve future treatments for others with RRMS.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with RRMS according to 2017 revised McDonald criteria
• • Patients who switched a previous first or second line DMT to ozanimod between 4 and 12 weeks before the enrollment
• • Patient with a MRI performed within three months before the enrollment
• • Patient eligible to ozanimod according to SmPC
• Exclusion Criteria:
• • Patients with clinical forms of MS other than RRMS
• • Patients unable to participate for various reasons
• • Patients participating in another clinical study with an investigational product if the study considers the switching behavior as an endpoint or objective
• • Contraindications to ozanimod according to SmPC
• • Other protocol-defined Inclusion/Exclusion Criteria apply.

Trial Officials